Glucose lq

To determine the induction of metabolic syndrome, we measured different parameters. Quantification of triglycerides, HDL, and uric acid was performed using commercial kits (Sekisui Diagnostics, Burlington, MA, USA). Glucose was measured with a commercial kit according to the manufacturer’s instructions (Glucose-LQ, Spinreact, Girona, Spain). All parameters were read in a hybrid multimode reader (Sinergy H1, Biotek-Agilent, Santa Clara, CA, USA).

Quantification of glucose (Glucose-LQ, Spinreact, Girona, Spain), triglycerides (Triglycerides-LQ, Spinreact, Girona, Spain), and uric acid (Sekisui Diagnostics, Burlington, MA, USA) was performed using commercial kits according to the manufacturer’s instructions.

Serum insulin (μU/mL) was quantified utilizing a commercial kit (Linco Research, St. Louis, MO) based on radioimmunoanalysis. A value >12 μU/mL was considered as hyperinsulinemia as was previously reported [21 (link)]. Serum glucose (mg/dL) concentration was measured by the glucose-oxidase method (Glucose-LQ, SpinReact, S.A., Girona, Spain). IR was calculated from insulin and glucose data using the homeostasis model assessment-insulin resistance (HOMA-IR) method (HOMA-IR = [fasting insulin, μU/mL] ∗ [fasting glucose, mmol/L])/22.5 [22 (link)]. Values of HOMA-IR > 3.16 [23 (link)] were considered as IR.